Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2019 / Cilt: 29 - Sayı: 1

Langerhans Cell Histiocytosis: Excellent Local Control with Low Dose Radiotherapy

Langerhan Hücreli Histiositozis: Düşük Doz Radyoterapi ile Mükemmel Lokal Kontrol

Pages
7–13
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Low dose local RTseems to be effective and safe in multidisciplinary management of LCH.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Langerhans cell histiocytosis (LCH) is a rare disorder.
📊
Key Findings & Data:The medical records of biopsy proven all LCH patients referred to ourcenter and treated with RT between 2000-2016 were evaluated retrospectively.
💡
Conclusion & Impact:Low dose local RTseems to be effective and safe in multidisciplinary management of LCH.
🔬Design:Review & Systematic Survey
📍Scope:2000-2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Langerhans cell histiocytosis (LCH) is a rare disorder. Uncontrolled clonal proliferation of langerhans cells leads to a diversity of clinicalmanifestations. Low dose Radiotherapy (RT) is used mainly for osseous manifestations as a sole treatment or in combination withsurgery/chemotherapy/steroids. Altough the mechanism of action of RT is an unresolved issue, it’s usually used in adjuvant/palliativesettings, also as first-line local therapy with curative intent in unresectable or resectable cases in case surgery would result in functional compromise. This study is conducted to review indications, dose-fractionation schedules, clinical characteristics and outcomesof LCH patients received local RT mainly for osseous lesions. The medical records of biopsy proven all LCH patients referred to ourcenter and treated with RT between 2000-2016 were evaluated retrospectively. Disease-free survival (DFS), local control and sideeffects were defined as study end-points. There was 35 patients, 21 of them were children. At presentation 65.7% had single systemsingle bone, 20% had single system-multiple bone, 15% had multisystem disease.Soft tissue extension were detected in 16 children,4 adults (p= 0.013).Mean radiation dose was 10.8 Gy. Median follow-up from the date of biopsy was 105 months (range= 8-204) inchildren and 88 (range:31-245) in adults (log rank p:0.029).Complete response rate was 97%. 11 children and 1 adult experiencedrelapse (p= 0.05), median interval for relapse was 9months in children, 19months in adults. The most common relapse pattern wasas single system-multiple bone (58.3%). Local control was 97.1%. Median disease free survival was 85 months. Low dose local RTseems to be effective and safe in multidisciplinary management of LCH.

Özet

Langerhans hücreli histiositozis (LCH), langerhans hücrelerine benzer dentritik hücrelerin çeşitli organlarda birikimi ve kontrolsüz klonal çoğalması ile karakterize, nadir görülen bir hastalıktır. Düşük doz radyoterapi (RT) ağrılı ve stabil olmayan kemik lezyonları ve kemik dışı yumuşak doku lezyonlarının tedavisinde tek başına ve/veya cerrahi, kemoterapi, steroidlerle birlikte kullanılmaktadır. Etki mekanizması halen net olarak anlaşılmamıştır. RT genelde adjuvant ve palyatif endikasyonlarda, ayrıca rezeke edilemeyen veya cerrahinin fonksiyonel hasar yaratabileceği rezektable olgularda küratif amaçlı olarak kullanılmaktadır. Bu çalışmada, çoğunlukla kemik lezyonlarına yönelik lokal RT uygulanan LCH tanılı olgularda klinik özellikler, RT endikasyonları, doz-fraksiyonizasyon şemaları ve tedavi sonuçlarının araştırılması amaçlanmıştır. 2000-2016 tarihlerinde kliniğimizde RT uygulanan biopsi ile kanıtlanmış tüm LCH tanılı olguların tedavi ve izlem kayıtları geriye dönük olarak değerlendirilmiştir. Hastalıksız sağkalım, lokal kontrol ve geç yan etki çalışmanın sonlanım noktaları olarak belirlenmiştir. 35 olgu saptanmıştır. Ortanca yaşı 12 (6-27), 21 olgu (%60) pediatrik yaş grubundadır. Olguların %65.7’sinde tek sistem-tek kemik tutulumu, %20’sinde tek sistem-çoklu kemik tutulumu, %15’inde çoklu sistem tutulumu saptanmıştır. Pediatrik yaş grubundaki olguların 16’sında ve erişkinlerin 4’ünde kemik lezyonlarına yumuşak doku uzanımının eşlik ettiği tespit edilmiştir (p= 0.013). Ortanca RT dozu10,8 Gy’dir. Patolojik tanı tarihinden itibaren olan ortanca izlem süresi pediatrik olgularda 105 (18-195), erişkinlerde 88 (31-245) aydır. Tam yanıt oranı %97’dir. İzlemde 11 pediatrik, 1 erişkin olguda yineleme saptanmıştır (p= 0.05), yineleme için geçen ortanca süre pediatrik olgularda 9ay, erişkin olguda 19aydır.Ortanca hastalıksız sağkalım 85 ay (52-117) olarak tespit edilmiştir. En sık yineleme paterni tek sistem-çoklu kemik tutulumu olarak izlenmiştir.Lokal control %97.1’dir. Ortanca hastalıksız sağkalım 85 aydır. LCH’de düşük dozda RT multidisipliner tedavinin bir parçası olarak, etkin lokal kontrol sağlayabilen, güvenilir bir tedavi seçeneğidir.

🔖

Cite This Article

ANACAK, Y., KANTAR, M., KAMER, S., SAYDAM, G., KIRAKLI, E. K., ÇETİNGÜL, N. (2022). Langerhans Cell Histiocytosis: Excellent Local Control with Low Dose Radiotherapy. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 29 - Sayı: 1, 7–13. https://ajindex.com/articles/644756

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Kriz J, Eich HT, Bruns F, et al. Radiotherapy in langerhans cell histiocytosis - a rare indication in a rare disease. Radiat Oncol 8: 233, 2013
  2. Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol 37: 108-114, 2001
  3. Kilpatrick S E, Wenger D E, Gilchrist GS, et al. Langerhans Cell Histiocytosis (Histiocytosis-X) of Bone - a Clinicopathological Analysis of 263 Pediatric and Adult Cases. Cancer 76: 2471-2484, 1995
  4. Lian C, Lu Y, Shen S. Langerhans cell histiocytosis in adults: a case report and review of the literature. Oncotarget 7: 18678-18683, 2016
  5. Hutter C and Minkov M. Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies. Immunotargets Ther 5: 81-91, 2016
  6. Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs 13: 75-86, 2011
  7. Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr 212: 139-144, 2000
  8. Olschewski T and Seegenschmiedt MH. Radiotherapy for bony manifestations of Langerhans cell histiocytosis - Review and proposal for an international registry. Strahlentherapie Und Onkologie 182: 72-79, 2006
  9. Baumgartner I, von Hochstetter A, Baumert B, et al. Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol 28: 9-14, 1997
  10. Howarth D M, Gilchrist G S, Mullan B P et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 85: 2278-2290, 1999
  11. Lieberman P H, Jones C R, Steinman RM, et al. Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol 20: 519-552, 1996
  12. Willman C L, Busque L, Griffith BB, et al. Langerhans’-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med 331: 154-60, 1994
  13. Berres M L, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol 169: 3-13, 2015
  14. Braier J. Is Langerhans cell histiocytosis a neoplasia? Pediatr Blood Cancer 64:e26267, 2017
  15. Allen C E, Ladisch S, and McClain K L. How I treat Langerhans cell histiocytosis. Blood 126: 26-35, 2015
  16. Winkfield KM, Bazan JG, Eng TY, et al. Benign Diseases. In: Principles and Pract